Will IMVT-1402 cutaneous lupus Ph2 PoC readout be positive by 2027-03-31?
Current Prediction
Why This Question Matters
IMVT-1402 cutaneous lupus PoC is a Ph2 proof-of-concept expanding the FcRn franchise into dermatology autoimmune. Smaller than the RA readout in financial leverage but informative about mechanism breadth. A positive result supports the best-in-class FcRn narrative and provides third confirmatory indication post-Graves'. A negative result narrows the franchise thesis but does not invalidate Graves' which is the flagship. Relatively high model uncertainty because public Ph2 design detail is limited and CLE FcRn class base rates are sparse.
Prediction Distribution
Individual Predictions(9 runs)
Coin flip with context. Ph2 PoC has flexible framing — 'positive' typically means primary endpoint hit OR supportive secondary data that management characterizes as worth advancing. Base rate across all mechanisms ~55-65% for 'positive' framing. Discount to 50% for: (1) FcRn CLE precedent is weak — no prior CLE FcRn efficacy data; (2) CLASI endpoint has significant inter-rater variability; (3) batoclimab TED narrative pressure elevates FDA and market scrutiny on IMVT franchise. Upside: severe unmet need in refractory CLE, IMVT-1402 mechanistic improvement over batoclimab. Net 0.50.
Slight positive tilt. Three supportive factors: (1) CLE has clearer autoantibody component than some FcRn indications (anti-Ro, anti-La, anti-dsDNA involvement in subacute/discoid lupus) — mechanism-rationale plausible; (2) Ph2 PoC framing permits 'supportive' secondary data interpretation; (3) Immunovant portfolio diversification signals internal confidence across indications. Discount for CLASI variability and batoclimab narrative. Net 0.52.
Slight negative tilt. FcRn CLE mechanism-indication fit is inferred, not evidence-supported. The strict 'supportive of advancing' framing in resolution criteria raises the bar compared to pure statistical hit — management needs to explicitly commit to pivotal advancement. Given Immunovant's current focus on Graves' and D2T RA as priority indications, CLE likely treated as 'option value' where a marginal hit might not trigger explicit advancement commitment. Net 0.48.
Coin flip. Ph2 PoC flexible framing and CLE autoantibody rationale support ~55%; CLASI variability, batoclimab narrative, and 'supportive of advancing' strict criterion compress to ~50%.
Slight negative tilt. FcRn CLE precedent is weak; CLASI investigator-assessed endpoint has significant variability. Ph2 PoC framing helps but 'supportive of advancing' strictness offsets. Net 0.48.
Coin flip. Ph2 PoC flexible framing (~55%) discounted to 50% by FcRn CLE novelty and endpoint variability. Timing window generous.
Coin flip. Ph2 PoC framing flexibility offset by FcRn CLE novelty. Net 0.50.
Slight positive tilt from Ph2 PoC framing flexibility and CLE autoantibody rationale. Net 0.52.
Slight negative tilt. FcRn CLE precedent weak; CLASI variability high. Net 0.48.
Resolution Criteria
Resolves YES if, by 2027-03-31, Roivant or Immunovant discloses via 8-K, press release, or investor presentation that the IMVT-1402 CLE Ph2 PoC primary or co-primary endpoint was met, AND management characterizes the result as supportive of advancing to a pivotal trial or further development. Resolves NO if by 2027-03-31: (a) the primary endpoint was missed, (b) the trial was terminated for futility, (c) management characterizes the readout as not supporting further development, or (d) no topline readout has been disclosed.
Resolution Source
Roivant/Immunovant 8-K filings, press releases, ClinicalTrials.gov, investor presentations
Source Trigger
IMVT-1402 CLE Ph2 PoC readout (H2 CY2026)
Full multi-lens equity analysis